scholarly journals SHA 056. Prevalence and prognosis of congestive heart failure in Saudi patients admitted with acute coronary syndrome (from SPACE registry)

2011 ◽  
Vol 23 (3) ◽  
pp. 186
Author(s):  
Khalid Al Habib ◽  
Ahmed Hersi ◽  
Hussam Al-Faleh ◽  
Mohammed Rudwan Arafah ◽  
Mohammed Ibrahim Kurdi ◽  
...  
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Acute Coronary Syndrome ◽  
Coronary Syndrome ◽  
Saudi Patients

Prevalence and prognosis of congestive heart failure in Saudi patients admitted with acute coronary syndrome (from SPACE registry)

2013 ◽  
Vol 24 (7) ◽  
pp. 596-601 ◽  
Author(s):  
Hanan B. Albackr ◽  
Khalid F. AlHabib ◽  
Anhar Ullah ◽  
Hussam Alfaleh ◽  
Ahmad Hersi ◽  
...  
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Acute Coronary Syndrome ◽  
Coronary Syndrome ◽  
Saudi Patients

scholarly journals Stem Cell Therapy in Acute Coronary Syndrome

2006 ◽  
Vol 4 (1) ◽  
pp. 9-12
Author(s):  
Rajib Rajbhandari
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Acute Coronary Syndrome ◽  
Stem Cell ◽  
Cell Therapy ◽  
Stem Cell Therapy ◽  
Cardiovascular Medicine ◽  
Coronary Syndrome

Acule coronary syndrome and congestive heart failure are still among challenging problems in the field of cardiovascular medicine despite many advances in the field. Stem cell therapy has come as a new hope and a promise for the hopeless.

Outcome of Allogeneic Stem Cell Transplantation in Patients with Low Ventricular Ejection Fraction

Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 3306-3306
Author(s):  
Ziad U. Khan ◽  
Rima M Saliba ◽  
Suhail Qureshi ◽  
Chitra Hosing ◽  
Sergio A Giralt ◽  
...  
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Acute Coronary Syndrome ◽  
Stem Cell ◽  
Ejection Fraction ◽  
Stem Cell Transplantation ◽  
Cardiac Toxicity ◽  
Hematologic Malignancies ◽  
Ventricular Ejection Fraction ◽  
Coronary Syndrome

Abstract BACKGROUND: High-dose therapy and Allogeneic stem cell transplantation (allo SCT) is a potentially curative treatment for patients with hematologic malignancies. A high risk of regimen-related toxicity limits this treatment only for patients with excellent organ-system function. A low left ventricular ejection fraction (LVEF) of ≤ 45% is considered to be a major risk factor for post-transplant cardiac toxicity and nonrelapse mortality (NRM). However, several patients with advanced hematologic malignancies and low LVEF can potentially benefit from this therapy. To address this issue, we evaluated the frequency of cardiac toxicity and NRM in 56 patients with low LVEF undergoing allo SCT. METHODS: We performed a retrospective analysis on 56 patients with baseline low LVEF who received allo SCT between January 2000 and February 2006 at our institution. Pre-transplant evaluation included an electrocardiogram and bidimensional echocardiogram or gated cardiac scan. Cardiac toxicity was defined as congestive heart failure (CHF), atrial/ventricular arrhythmia or an acute coronary syndrome. Of the 56 patients, 22 received a myeloablative regimen (16 busulfan-based, 6 total body irradiation-based) while 34 patients received a fludarabine-based reduced intensity conditioning regimen. RESULTS: Twenty-three patients (41%) received allo SCT from an unrelated donor. Acute leukemia was the reason for allo SCT in 32 (57%) patients. Baseline LVEF within 30 days pre-transplant ranged 20 to 45%. At their 6 month follow-up, cardiac toxicity was seen in 7 (12%) patients. Toxicity included congestive heart failure (CHF) in 4 (7%) and atrial fibrillation (AF) in 4 (7%). One patient had both CHF and AF. There were no documented episodes of acute coronary syndrome. Cumulative incidence of NRM at 100 days was 12%; none of the deaths were attributable to cardiac causes. These results were comparable to allo SCT performed in patients with normal LVEF. Variables such as age, LVEF, type of transplant, or the underlying disease did not emerge as significant predictors of post-transplant cardiac toxicity or NRM. CONCLUSION: Patients with low LVEF (<45%) are acceptable candidates for allo SCT. A prospective study with stratification of cardiac risk factors is warranted in patients with low LVEF.

scholarly journals Pentraxin 3 as a Novel Marker Predicting Congestive Heart Failure in Subjects With Acute Coronary Syndrome

2010 ◽  
Vol 40 (8) ◽  
pp. 370 ◽  
Author(s):  
Dong-Hyeon Lee ◽  
Hui-Kyung Jeon ◽  
Ji-Han You ◽  
Mi-Yeon Park ◽  
Seung-Jae Lee ◽  
...  
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Acute Coronary Syndrome ◽  
Pentraxin 3 ◽  
Coronary Syndrome

scholarly journals Impact of In-Hospital Revascularization on Survival in Patients With Non–ST-Elevation Acute Coronary Syndrome and Congestive Heart Failure

Circulation ◽  
2008 ◽  
Vol 118 (11) ◽  
pp. 1163-1171 ◽  
Author(s):  
Philippe Gabriel Steg ◽  
Arthur Kerner ◽  
Frans Van de Werf ◽  
José López-Sendón ◽  
Joel M. Gore ◽  
...  
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Acute Coronary Syndrome ◽  
Coronary Syndrome ◽  
St Elevation ◽  
Elevation Acute Coronary Syndrome

Congestive heart failure complicating non-ST segment elevation acute coronary syndrome: incidence, predictors, and clinical outcomes

2005 ◽  
Vol 83 (1) ◽  
pp. 98-103 ◽  
Author(s):  
Shamir R Mehta ◽  
John W Eikelboom ◽  
Catherine Demers ◽  
Aldo P Maggioni ◽  
Patrick J Commerford ◽  
...  
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Acute Coronary Syndrome ◽  
Unstable Angina ◽  
Clinical Outcomes ◽  
St Segment Elevation ◽  
Risk Of Death ◽  
Coronary Syndrome ◽  
St Segment ◽  
Increased Risk

There are limited data regarding the incidence and clinical significance of congestive heart failure (CHF) in patients with non-ST segment elevation acute coronary syndromes (ACS). The objectives of this study were to examine the incidence, predictors, and clinical outcomes in patients with ACS without ST elevation who develop CHF. We studied patients with unstable angina or non-ST segment elevation myocardial infarction (NSTEMI) randomized to hirudin or unfractionated heparin in the Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) trial. The diagnosis of CHF was based on a combination of clinical and radiographic features. Patients were followed for 6 months. Of 10 141 randomized patients, 501 (4.9%) developed CHF within the first week and 643 (6.3%) during 6 months of followup. Independent predictors for the development of CHF were older age, female sex, diabetes, prior MI, prior CHF, and NSTEMI at presentation. Compared with patients who did not develop CHF, patients who developed CHF were at increased risk of death (odds ratio (OR) 3.4, 95% CI 2.7–4.3), new MI (OR 2.8, 95% CI 2.2–3.6), and the need for intra-aortic balloon pump insertion (OR 5.4, 95% CI 3.5–8.4) at 7 days and 6 months. There was no increase in use of cardiac catheterization (OR 0.8, 95% CI 0.7–1.0) or revascularization (OR 0.9, 95% CI 0.7–1.1) in patients who developed CHF. CHF is a common complication in patients presenting with non-ST segment elevation ACS and is strongly associated with adverse clinical outcomes including new MI and death. Despite this worse prognosis, patients with ACS developing CHF are less likely to be referred for invasive management.Key words: unstable angina, acute coronary syndrome, congestive heart failure, prognosis.

Sign in / Sign up

Export Citation Format

Share Document